外媒：中国癌症研究取得突破

▲全球视野 本土思考

癌症仍然是中国的重点疾病之一。

惠誉国际咨询公司(Fitch Solutions)的一份展望报告称，随着中国在先进癌症治疗方法的早期取得突破，中国将继续在抗癌药物的研究和治疗方面进行创新。

其中一些进展包括单克隆抗体和CAR-T疗法的进展。

中国生物科技初创企业越来越多，从2013年到2018年，中国的生命科学投资增长了1,287％。

当美国食品和药物管理局于2019年11月授权百济神州公司独立开发的Brukinsa（zanubrutinib）时，标志着中国抗癌药物的首次批准。

今年早些时候，该公司的抗pd -1抗体tislelizumab也获得了中国国家医药产品管理局的批准。

癌症仍是中国的五大重点疾病领域之一，2018年全球癌症病例数最高，达到每年400万例。该国的癌症死亡率也比美国高40%。

同时，中国政府对医疗保健政策进行了几项改革，以控制发病率的上升，包括实施抗癌药物零关税政策，接受海外临床试验数据以及以及采取措施加快癌症药物审批。＊

China sees breakthroughs in cancer research

Cancer remains amongst China’s high-priority disease areas.

China continues to innovate on their anti-cancer drug research and treatment as they make early breakthroughs in therapies derived from advanced cancer treatments, according to an outlook by Fitch Solutions.

Some of these developments include advances in monoclonal antibodies and CAR-T therapies.

Amidst a growing number of biotech start-ups in the country, China saw a 1,287% growth in life science investment from 2013 to 2018.

The country marked its first-ever approval for a Chinese anti-cancer drug when the US Food and Drug Administration authorized BeiGene’s independently developed Brukinsa (zanubrutinib) in November 2019. The company’s anti-PD-1 antibody tislelizumab was also approved by China's National Medical Products Administration earlier this year.

Cancer remains amongst China’s five high-priority disease areas, with them having the largest number of cases globally at four million per year in 2018. The country’s cancer mortality rate is also 40% higher than that of the US.

Meanwhile, the Chinese government has made several reforms on healthcare policy to manage the rising rates of incidence, including the implementation of a zero-tariff policy on anti-cancer drugs, acceptance of overseas clinical trial data, and adoption of measures to speed up the approval of cancer medicines.